Nymox Pharmaceutical Corporation (NYMX): Price and Financial Metrics

Nymox Pharmaceutical Corporation (NYMX): $0.20

0.05 (-19.68%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add NYMX to Watchlist
Sign Up

NYMX Price/Volume Stats

Current price $0.20 52-week high $0.74
Prev. close $0.25 52-week low $0.17
Day low $0.18 Volume 932,700
Day high $0.22 Avg. volume 94,622
50-day MA $0.39 Dividend yield N/A
200-day MA $0.38 Market Cap 18.10M

NYMX Stock Price Chart Interactive Chart >


Nymox Pharmaceutical Corporation (NYMX) Company Bio


Nymox Pharmaceutical Corporation engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer’s disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company was founded in 1989 and is based in Nassau, The Bahamas.


NYMX Latest News Stream


Event/Time News Detail
Loading, please wait...

NYMX Latest Social Stream


Loading social stream, please wait...

View Full NYMX Social Stream

Latest NYMX News From Around the Web

Below are the latest news stories about NYMOX PHARMACEUTICAL CORP that investors may wish to consider to help them evaluate NYMX as an investment opportunity.

NYMOX Update

IRVINE, Calif., July 07, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing information to address requests it has received for further information concerning recent changes to the Company’s Board of Directors (“Board”) and the Company’s management. Two former employees (the “Former Employees”) of the Company proposed to the Company a potential transaction (the “Proposed Transaction”). The Company, its employees, and the Former Employees

Yahoo | July 7, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day off right with a breakdown of the biggest pre-market stock movers traders need to watch on Thursday!

William White on InvestorPlace | July 6, 2023

Why Is Kazia Therapeutics (KZIA) Stock Moving Today?

Kazia Therapeutics (KZIA) stock is on the move Thursday after the company received fast-track designation for its paxalisib program.

William White on InvestorPlace | July 6, 2023

Why Is Nymox Pharmaceutical (NYMX) Stock Down 18% Today?

Nymox Pharmaceutical (NYMX) stock is falling on Thursday after the company told investors its shares will be delisted tomorrow.

William White on InvestorPlace | July 6, 2023

Nymox Delisting from NASDAQ

IRVINE, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month extension period granted by Nasdaq, and hence the Company's shares will be suspended from trading on NASDAQ at the open of business on July 7, 2023. Nymox shares will be moved to the OTC market. The mechanics of trading the stock remain the same, as do

Yahoo | July 5, 2023

Read More 'NYMX' Stories Here

NYMX Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year -53.49%
3-year -90.15%
5-year -89.19%
YTD N/A
2023 0.00%
2022 -75.13%
2021 -47.58%
2020 12.73%
2019 67.94%

Continue Researching NYMX

Here are a few links from around the web to help you further your research on Nymox Pharmaceutical Corp's stock as an investment opportunity:

Nymox Pharmaceutical Corp (NYMX) Stock Price | Nasdaq
Nymox Pharmaceutical Corp (NYMX) Stock Quote, History and News - Yahoo Finance
Nymox Pharmaceutical Corp (NYMX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!